Karen L. Lobb

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 84 citations · Full text

Kinase Inhibitors, Pharmaceutical Chemistry, Tumor Biology +20

Potent and Selective 1,2,3-Trisubstituted Indole NPY Y-1 Antagonists

Philip A. Hipskind, Karen L. Lobb, James A. Nixon et al. · Journal of Medicinal Chemistry · 1997 · 81 citations · Full text

Pharmaceutical Science, Altmetric Attention Score, Pharmacotherapy +16

Acyl Sulfonamide Anti-Proliferatives:  Benzene Substituent Structure−Activity Relationships for a Novel Class of Antitumor Agents

Karen L. Lobb, Philip A. Hipskind, James Aikins et al. · Journal of Medicinal Chemistry · 2004 · 67 citations · Full text

Organic Chemistry, Chemistry, Human Tumor Xenografts +16

Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.

Bruce D. Gitter, Robert F. Bruns, J. Jeffry Howbert et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 60 citations

LY303870, a Centrally Active Neurokinin-1 Antagonist with a Long Duration of Action

Satish Iyengar, Philip A. Hipskind, Donald R. Gehlert et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 58 citations